期刊文献+

影响子宫内膜不典型增生诊断的临床因素 被引量:4

Clinical influencing factors of diagnosis of atypical endometrial hyperplasia
原文传递
导出
摘要 目的:探讨子宫内膜不典型增生(AEH)的临床特点和影响诊断的相关因素。方法:回顾性分析广西医科大学第一附属医院77例术前诊断为AEH患者的临床病理资料,根据术后病理诊断分为子宫内膜癌组(A组,50例)和AEH组(B组,27例)进行比较分析。结果:A组全部为子宫内膜样腺癌,占64.9%,B组占35.1%;两组年龄比较,t=2.708,P=0.008<0.05,差异有统计学意义;术后病理诊断与术前诊刮AEH的分度有关,轻、中、重度AEH合并子宫内膜癌率分别为28.6%、42.1%、78.4%;两组肿瘤标记物CA125比较,P=0.140>0.05,差异无统计学意义。结论:①年龄是AEH合并子宫内膜癌的高危因素;②随着诊刮AEH分度增加,合并子宫内膜癌有增加趋势;合并子宫内膜癌多数分化较好、浸润少、期别以Ⅰ期为主。③血清CA125不是预测AEH合并子宫内膜癌的敏感指标。 Objective: To explore the clinical characteristics of atypical endometrial hyperplasia (AEH) and the related influen- cing factors. Methods: The clinicopathological data of seventy - seven patients diagnosed as AEH in the hospital preoperatively were ana- lyzed retrospectively, then they were divided into two groups according to postoperative pathological diagnosis: endometrial cancer group (group A, 50 cases) and AEH group (group B, 27 cases) , the results in the two groups were compared, l^esults: The cases in group ~'~ were diagnosed as endometrioid adenocarcinoma, which accounted for 64. 9% , and the cases with endometrioid adenocarcinoma in group B accounted for 35.1%. There was statistically significant difference in age between the two groups ( t = 2. 708, P = 0. 008 ) . The postol)cra- tire pathological diagnosis was associated with preoperative degree of AEH after uterine curettage: the coexistence rates of endometrial carcinoma with AEH of slight, moderate, and high degrees were 28.6% , 42. 1% , and 78.4%, respectively. There was no statistically signifi- cant difference in the concentration of tumor marker (CA125) between the two groups (P 〉 0. 05) . Conclusion: Age is a high risk factor for coexistence with endometrial carcinoma. With the progression of AEH degree, the trend of coexistence with endometrial carcinoma en- hances. The coexistent with endometrial carcinoma is mostly staged in FIGO I with high differentiation and less infiltration. Sermn CA125 is not a sensitive index for indicating AEH coexisting with endometrial carcinoma.
出处 《中国妇幼保健》 CAS 北大核心 2013年第9期1424-1426,共3页 Maternal and Child Health Care of China
关键词 子宫内膜不典型增生 子宫内膜癌 诊断性刮宫 Atypical endometrial hyperplasia Endometrial carcinoma Diagnostic curettage
  • 相关文献

参考文献7

二级参考文献47

  • 1刘木彪,何援利.子宫内膜电切术治疗子宫内膜不典型增生的初步探讨[J].中国内镜杂志,2006,12(6):587-589. 被引量:10
  • 2刘玉环,夏恩兰,曲静,黄晓武,郑杰,于丹,彭雪冰.子宫内膜非典型性增生的手术疗效探讨[J].中国内镜杂志,2006,12(8):812-814. 被引量:19
  • 3Matorras R Rodriguez FJ, Diez J, et al. Monitoring endometrial adenocarcinoma with a four tumor marker combination. CA125,squamous cell carcinoma antigen, CA19-9, and CA15-3[J]. Acta Obstet Gynecol Scand, 1992,71(3):458-464.
  • 4Rose PG, Reale ML, Beurskens ML, Hunter RE. Preoperative CA-125 levels predict poor prognostic pathologic features in early stage, FIGO grade 1 and 2 endometrial adenocarcinoma[J]. Int J Gynecol Cancer, 1993:3(3):259-263.
  • 5Rose PG, Sommers RM, Reale FR, et al. Serial serum CA125 measurement for evaluation of recurrence in patients with endometrial carcinoma[J]. Obstet Gynecol, 1994,84(1):12-16.
  • 6Bast RC Jr, Feeney M, Lazarus H, et al. Reactity of a monoclonal antibody with human ovarian carcinoma[J]. J Clin Invest,1981,68(5):1331-1337.
  • 7Donald E, Pittaway D. The use of serial CA125 concentrations to monitor endometriosis in infertile women[J]. Am J Obstet Gynecol, 1990;163(3):1032-1037.
  • 8Scambia G, Gadducci A, Panici PB, et al. Combined use of CA125 and CA15-3 in patients with endometrial carcinoma[J]. Gynecol Oncol, 1994,54(3):292-297.
  • 9Akeshima N, Shimizu Y, Umezawa S, et al. Combined assay of serum levels of CA125 and CA19-9 in endometrial carcinoma[J]. Gynecol Oncol, 1994,54(3):321-326.
  • 10Sood AK, Buller RE, Burger RA, et al. Value of preoperative CA125 level in the management of uterine cancer and prediction of clinical outcome[J]. Obstet Gynecol, 1997,90(3):441-447.

共引文献38

同被引文献29

引证文献4

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部